Activity Description and Educational Objectives

In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia.

Upon completion of this activity, participants should be better able to:

• Recognize the burden of anemia in patients with chronic kidney disease
• Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention
• Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease
• Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization

Target Audience

This activity has been designed to meet the educational needs of nephrologists, primary care physicians, and other clinicians involved in the care of patients with CKD-associated anemia.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 11, 2019 - June 10, 2020
Time to Complete: 30 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director

Jay B. Wish, MD
Professor of Clinical Medicine
Chief Medical Officer for Dialysis
Indiana University Health
Indianapolis, Indiana

Jay B. Wish, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Akebia Therapeutics; Astrazeneca; Otsuka America Pharmaceutical, Inc.; and Vifor Pharma Management Ltd.
Speakers Bureau participant with Keryx Biopharamceuticals, Inc. and Pfizer Inc.

Jay B. Wish, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) enzyme inhibitors for the treatment of anemia in CKD.

Content Reviewer

Matthew A. Goodman, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca LP.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView